|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
139,126,000 |
Market
Cap: |
125.41(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.8871 - $4.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
17,438 |
35,533 |
57,514 |
116,582 |
Total Sell Value |
$26,639 |
$61,294 |
$139,194 |
$443,003 |
Total People Sold |
3 |
5 |
5 |
9 |
Total Sell Transactions |
3 |
9 |
12 |
23 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-09-10 |
4 |
OE |
$24.47 |
$36,705 |
D/D |
1,500 |
36,995 |
|
- |
|
Mandell James |
Director |
|
2018-09-10 |
4 |
AS |
$150.06 |
$150,771 |
D/D |
(1,000) |
1,000 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2018-09-05 |
4 |
AS |
$161.83 |
$293,441 |
D/D |
(1,800) |
31,871 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2018-09-05 |
4 |
OE |
$50.51 |
$83,226 |
D/D |
1,300 |
33,671 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-09-04 |
4 |
AS |
$165.53 |
$1,166,493 |
D/D |
(7,000) |
24,905 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-09-04 |
4 |
OE |
$5.50 |
$38,503 |
D/D |
7,000 |
31,905 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-08-30 |
4 |
AS |
$175.37 |
$3,507,948 |
D/D |
(20,000) |
35,495 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-08-30 |
4 |
OE |
$2.09 |
$217,689 |
D/D |
20,000 |
55,495 |
|
- |
|
Finger Alison Cecily |
Chief Commercial Officer |
|
2018-08-20 |
4 |
S |
$158.05 |
$40,940 |
D/D |
(259) |
15,667 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-08-10 |
4 |
AS |
$155.41 |
$235,389 |
D/D |
(1,500) |
35,495 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-08-10 |
4 |
OE |
$5.50 |
$8,251 |
D/D |
1,500 |
36,995 |
|
- |
|
Cole Jason |
Chief Legal Officer |
|
2018-08-08 |
4 |
OE |
$22.53 |
$99,988 |
D/D |
4,438 |
21,610 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2018-08-06 |
4 |
AS |
$156.51 |
$281,889 |
D/D |
(1,800) |
32,371 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2018-08-06 |
4 |
OE |
$50.51 |
$83,226 |
D/D |
1,300 |
34,171 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-08-02 |
4 |
AS |
$150.31 |
$3,268,493 |
D/D |
(21,500) |
35,495 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-08-02 |
4 |
OE |
$5.50 |
$118,259 |
D/D |
21,500 |
56,995 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-08-02 |
4 |
AS |
$150.18 |
$1,052,585 |
D/D |
(7,000) |
24,905 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-08-02 |
4 |
OE |
$5.50 |
$38,503 |
D/D |
7,000 |
31,905 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-07-11 |
4 |
AS |
$180.15 |
$540,443 |
D/D |
(3,000) |
24,905 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-07-11 |
4 |
OE |
$5.50 |
$16,501 |
D/D |
3,000 |
27,905 |
|
- |
|
Cole Jason |
Chief Legal Officer |
|
2018-07-09 |
4 |
AS |
$168.47 |
$872,715 |
D/D |
(5,126) |
17,172 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-07-02 |
4 |
AS |
$153.36 |
$1,539,604 |
D/D |
(10,000) |
24,905 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-07-02 |
4 |
OE |
$5.50 |
$55,004 |
D/D |
10,000 |
34,905 |
|
- |
|
Dixon Wendy L |
Director |
|
2018-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
3,000 |
|
- |
|
Schenkein David P |
Director |
|
2018-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
4,176 |
|
- |
|
864 Records found
|
|
Page 15 of 35 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|